Rhone-poulenc Rorer Pharmaceuticals Inc.

Daniel G McGarry

William R Ewing

Alfred P Spada

John R Regan

Heinz W Pauls

Michael N Chang

Yong Mi Choi-Sledeski

Michael R Becker

Roderick S Davis

Jeffrey N Barton

Jack Newman

Schmuel Ben-Sasson

Francis A Volz

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Substituted sulfonic acid

This invention relates to aromatic oligomeric compounds useful in the treatment of cardiovascular, bone metabolic, hypolipidaemic, neuronal, gastrointestinal and elastase-mediated connective tissue degradation disorders and disorders which may be treated by agents effective in binding DNA, to processes for preparation of such oligomeric compounds, to pharmaceutical compositions including such oligomeric compounds, and to their use in the treatment of such disorders.

Aromatic oligomeric compounds useful as mimics of bioactive

This invention relates to compounds which are steroidyl derivatives of 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one and the corresponding ring-opened hydroxy acid form thereof which are useful as antihypercholesterolemic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypercholesterolemia.

Compounds having hypocholesterolemic properties

Growing community of inventors

King of Prussia, PA, United States of America

Daniel G McGarry